Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 1 (1)
P 3 (2)

Trial Status

Not Yet Recruiting1
Withdrawn1
Active Not Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT04712097Phase 3Active Not RecruitingPrimary

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

NCT06313996Phase 3WithdrawnPrimary

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

NCT07343934Phase 1Not Yet RecruitingPrimary

huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma

Showing all 3 trials

Research Network

Activity Timeline